Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing

Infringement and plausibility were the biggest issues on the battleground in the UK Supreme Court’s hearing in a case dealing with second medical use patents, as Claire Phipps-Jones, Katie Cambrook and Rachel Mumby of Bristows report.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

15 November 2018 The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.

Big Pharma

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Big Pharma

UK Supreme Court grants BIA intervention request in plausibility case

18 January 2018 The UK Supreme Court has granted the UK BioIndustry Association permission to intervene in the case of Warner-Lambert Company v Generics and Actavis, which concerns the issue of ‘plausibility’.